A
Alice Cani
Researcher at University of Ferrara
Publications - 17
Citations - 469
Alice Cani is an academic researcher from University of Ferrara. The author has contributed to research in topics: PI3K/AKT/mTOR pathway & Protein kinase B. The author has an hindex of 8, co-authored 11 publications receiving 393 citations.
Papers
More filters
Journal ArticleDOI
Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential.
Luca M. Neri,Alice Cani,Am Martelli,Carolina Simioni,Christian Junghanss,Giovanna Tabellini,Francesca Ricci,P. L. Tazzari,Pasqualepaolo Pagliaro,James A. McCubrey,Silvano Capitani +10 more
TL;DR: It is pointed out that mTORC1 inhibitors, either as a single agent or in combination with Akt inhibitors, could represent a potential therapeutic innovative strategy in B-pre ALL.
Journal ArticleDOI
Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia.
Carolina Simioni,Luca M. Neri,Giovanna Tabellini,Francesca Ricci,Daniela Bressanin,Francesca Chiarini,Camilla Evangelisti,Alice Cani,P. L. Tazzari,Fraia Melchionda,Pasqualepaolo Pagliaro,Andrea Pession,James A. McCubrey,Silvano Capitani,Alberto M. Martelli,Alberto M. Martelli +15 more
TL;DR: The effects of the novel allosteric Akt inhibitor, MK-2206, on a panel of human T-ALL cell lines and primary cells from T-all patients indicate that Akt inhibition may represent a potential therapeutic strategy in T- ALL.
Journal ArticleDOI
miR-199a-3p Modulates MTOR and PAK4 Pathways and Inhibits Tumor Growth in a Hepatocellular Carcinoma Transgenic Mouse Model.
Elisa Callegari,Lucilla D'Abundo,Paola Guerriero,Carolina Simioni,Bahaeldin K. Elamin,Marta Russo,Alice Cani,Cristian Bassi,Barbara Zagatti,Luciano Giacomelli,Stella Blandamura,Farzaneh Moshiri,Simona Ultimo,Antonio Frassoldati,Giuseppe Altavilla,Laura Gramantieri,Luca M. Neri,Silvia Sabbioni,Massimo Negrini +18 more
TL;DR: The therapeutic efficacy of miR-199a-3p, an miRNA highly expressed in normal liver and downregulated in virtually all HCCs, is investigated and suggested that it may be considered a promising HCC therapeutic option.
Journal ArticleDOI
Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation
Carolina Simioni,Alice Cani,Alberto M. Martelli,Giorgio Zauli,Giovanna Tabellini,James A. McCubrey,Silvano Capitani,Luca M. Neri +7 more
TL;DR: Torin-2 alone suppressed feedback activation of PI3K/Akt, whereas the mTORC1 inhibitor RAD001 required the addition of the Akt inhibitor MK-2206 to achieve the same effect.
Journal ArticleDOI
The AKT Inhibitor MK-2206 is Cytotoxic in Hepatocarcinoma Cells Displaying Hyperphosphorylated AKT-1 and Synergizes with Conventional Chemotherapy
Carolina Simioni,Alberto M. Martelli,Alice Cani,Rengul Cetin-Atalay,James A. McCubrey,Silvano Capitani,Luca M. Neri +6 more
TL;DR: The findings suggest that the use of Akt inhibitors, either alone or in combination with doxorubicin, may be considered as an attractive therapeutic regimen for the treatment of HCC.